

Pharmacy Formulary Updates for November 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in November 2018:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Adcirca	NC;SP
tadalafil tablets	T2;PA;SP
Ampyra	NC;SP
dalfampridine	T2;PA;QL;SP
Ozempic	T2
doxycycline hyclate 50 mg tablets	NC
Rhopressa	T3;STPA
itraconazole solution	T2
Sporanox solution	NC
Andexxa	MB
Olumiant	T2;PA;SP
Dexycu	MB
Lonhala Magnair	NC
Kaspargo	NC
Butalbital/Acetaminophen 50/300 mg capsules	NC
Orkambi	T2;PA;QL
albendazole	T2
Albenza	NC
morphine sulfate ER 40 mg	T1;QL
Kadian 40 mg	NC;QL

Key:

MB: Medical Benefit	QL: Quantity Limitation
NC: Not covered	SP: Specialty Pharmacy - provided through CVS/specialty
NTM: New-to-market	ST: Step Therapy
PA: Prior Authorization	